The Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Ameluz ® (aminolevulinic acid HCI) topical gel, 10% allowing for a larger field of treatment in patients ...
While the early introduction of etanercept led to more rapid disease control among patients with difficult-to-treat rheumatoid arthritis, it did not provide superior long-term disease control over 2 ...